Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 156 Cr.
- Current Price ₹ 95.2
- High / Low ₹ 160 / 75.2
- Stock P/E 11.5
- Book Value ₹ 49.9
- Dividend Yield 0.00 %
- ROCE 26.9 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 153 days to 346 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | |
| 29 | 53 | 54 | 67 | 88 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 |
| OPM % | 5% | 11% | 13% | 19% | 15% |
| 0 | 0 | 0 | 0 | 4 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 |
| Tax % | 18% | 29% | 28% | 30% | 27% |
| 1 | 4 | 5 | 10 | 14 | |
| EPS in Rs | 8.45 | 8.28 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 32% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 |
| 3 | 3 | 4 | 5 | 30 | |
| 9 | 22 | 28 | 26 | 10 | |
| Total Liabilities | 18 | 35 | 47 | 59 | 122 |
| 6 | 7 | 10 | 10 | 12 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 52 |
| 12 | 27 | 37 | 49 | 58 | |
| Total Assets | 18 | 35 | 47 | 59 | 122 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | |
| -1 | -2 | -4 | -5 | -44 | |
| 0 | -0 | 0 | 2 | 67 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 104 | 105 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 |
| Days Payable | 119 | 140 | 215 | 137 | 26 |
| Cash Conversion Cycle | 3 | 4 | 1 | 79 | 178 |
| Working Capital Days | 31 | 25 | 40 | 74 | 346 |
| ROCE % | 55% | 47% | 58% | 27% |
Documents
Announcements
-
Updates
17 July 2025 - Board meeting on July 24 to approve Q1 June 30, 2025 unaudited financial results.
-
Updates
17 July 2025 - Exchange cautions company for delayed disclosure of director resignation, urges corrective measures.
-
Board Meeting Intimation
17 July 2025 - QUEST LABORATORIES LIMITED has informed about Board Meeting to be held on 24-Jul-2025 to inter-alia consider and approve the Unaudited Financial results of the Company …
-
Structural Digital Database
11 July 2025 - Structured Digital Database Certificate for quarter ended JUNE 2025
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
10 July 2025 - Confirmation of full demat shareholding and no rematerialisation requests for Q1 FY2025-26.
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar